Red Tree Venture Capital

🚀 Exciting News from Kivu Bioscience! 🌟 We’re thrilled to share that Kivu has officially launched with a substantial $92 million in funding! This innovative biotech, spun out from Synaffix, is set to transform the landscape of antibody-drug conjugates (ADCs). Kivu is focused on developing next-generation Topo1i-based therapies that offer higher dosages and reduced toxicity to healthy tissues. With plans to enter human trials for its first ADC, KIVU-107, next year, the potential impact on oncology treatment is immense. Stay tuned for more updates as Kivu embarks on its journey to transform cancer treatment! Read more here: https://lnkd.in/ep8aDTTz #Biotech #ADC #Innovation #Oncology #KivuBioscience

🎉 Exciting news! Congratulations to the Ceribell │ AI-Powered Point-of-Care EEG team on their successful upsized IPO! 🚀 This milestone is a testament to the team's hard work, innovation, and dedication to transforming the landscape of neurology with AI. Thrilled to see the vision come to life and looking forward to the amazing impact they will continue to make in the healthcare sector. Here's to a bright future ahead! 🌟 #Ceribell #InnovationInHealthcare #LifeSciences #Biotech #IPO 🍭

We are excited to announce that Antonio Lepore, PhD has joined Red Tree as a Senior Associate on the investment team! Antonio brings a wealth of knowledge in early-stage biotech strategy, business development, and operations from his time at Resonance Medicine, Fusion Pharmaceuticals, Navigant Consulting (now Guidehouse), and as an independent advisor to life science startups. Delighted to have him on board!

Congratulations to the Bicara Therapeutics team on their upsized IPO! 🚀 🎉 We can't wait to see the transformative impact Bicara's innovative therapies will have on the future of oncology and the meaningful difference they will make for cancer patients. #BicaraTherapeutics #Healthcare #LifeSciences #Biotech #Oncology #IPO 🍭

Thank you to Nature Portfolio and Biopharma Dealmakers for the recent coverage of Engrail Therapeutics and how we are de-risking drug development through precision neuroscience. You can download/view the article here: https://lnkd.in/gWPGsw6W

We are pleased to see Red Tree Partner Jeremy Caldwell featured at AlphaCore's Wealth Summit, where he will discuss the latest advancements in the life sciences industry!